Book Value per Share: Sensei Biotherapeutics (SNSE)

Graphic logo of Sensei Bio (SNSE)

The targeted therapy ecosystem relies on trials of the SNS-101 drug, where the molecule's safety profile attracts patients. The book value per share reflects capital dynamics, with the 18.36 mark serving as a key metric. Sensei Biotherapeutics (SNSE) is developing TMAb platforms for B2B licensing in oncology, utilizing innovative ImmunoPhage technology for precise antigen targeting without chemical toxicity.

SNSE: Sensei Biotherapeutics Net Asset Value per Share 07/04/2022 - 06/16/2026

Sensei Biotherapeutics Inc - analytical breakdowns and key metrics (SNSE)

- price and consensus price forecast:
Price Chart Sensei Bio|SNSE - Analyst Median Target
- market capitalization data:
Market Capitalization Sensei Biotherapeutics, Inc.|SNSE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Sensei Biotherapeutics|SNSE - Total Stockholders' Equity|Market Value to Book Value Ratio senseibio.com|SNSE - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Sensei Biotherapeutics|SNSE - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Sensei Bio|SNSE - Company Cumulative Debt|Debt to Book Capitalization Ratio Sensei Biotherapeutics, Inc.
Fundamental company valuation:SNSE - senseibio.com
Flagship merchandise of Sensei Bio

Developing personalized cancer vaccines via the ImmunoPhage platform requires significant capital expenditures, which is reflected in the equity dynamics of Sensei Biotherapeutics (SNSE). By analyzing the company's book value per share, an investor can identify the actual volume of net assets per security stripped of market speculation, where an upward trend confirms a growing asset base, while a purchase price that is inflated relative to this metric signals potential risks.

Competitor analysis for Sensei Biotherapeutics

Net Assets per Single Share IBRX (ImmunityBio Corp)|IMCR - Net Assets per Share|Book Value per Share JANX|RCUS (arcusbio.com) - Net Asset Value per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|IMMX - Net Asset Value per Share|Accounting Value per Share ALX Oncology Holdings (ALXO)|CUE - Accounting Value of a Share|pdsbiotech.com - Book Value per Share|SONN (Sonnet BioTherapeutics Holdings) - Net Assets per Share|Net Assets per Single Share MAIA|Accounting Value per Share LIMN|Net Assets per Single Share LVTX (LAVA Therapeutics N.V.)|Accounting Value per Share nextcure.com NXTC|Accounting Value per Share LPTX (Leap Therapeutics)|Intensity Therapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx